Prolymphocytic leukemia: a very satisfactory response to treatment with recombinant interferon alpha.
We report the case of a patient with prolymphocytic leukemia in whom a lengthy survival of 5 years was observed after treatment with splenic irradiation and chemotherapy. The patient obtained a surprising improvement with a significant reduction in the absolute count of the prolymphocytes and considerable reduction in splenomegaly after 3 months' therapy with interferon alpha.
Vivaldi
P
P
Dipartimento di Geriatria, Ospedale Generale S. Chiara, Trento, Italy.
Garuti
R
R
Rubertelli
M
M
Mazzon
C
C
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001772:Blood Cell Count / Q000187:drug effects; D001803:Blood Transfusion; D002699:Chlorambucil / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D006801:Humans; D006971:Hypersplenism / Q000209:etiology / Q000628:therapy; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015463:Leukemia, Prolymphocytic / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D013163:Splenomegaly / Q000209:etiology / Q000532:radiotherapy; D014750:Vincristine / Q000008:administration & dosage
D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002699:Chlorambucil; D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone